OTCMKTS:BIOAFbiOasis Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding biOasis Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.25 0.00 (0.00 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.23Now: $0.25▼$0.2650-Day Range$0.11MA: $0.15▼$0.2552-Week Range$0.09Now: $0.25▼$0.26Volume22,945 shsAverage Volume19,112 shsMarket Capitalization$16.71 millionP/E RatioN/ADividend YieldN/ABeta0.12 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the BBB; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program, as well with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for biOasis Technologies. Previous Next 2.2 Community Rank Outperform VotesbiOasis Technologies has received 61 “outperform” votes. (Add your “outperform” vote.)Underperform VotesbiOasis Technologies has received 77 “underperform” votes. (Add your “underperform” vote.)Community SentimentbiOasis Technologies has received 55.80% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote “Outperform” if you believe BIOAF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIOAF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldbiOasis Technologies does not currently pay a dividend.Dividend GrowthbiOasis Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, biOasis Technologies insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Drugs, proprietaries, & sundries Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BIOAF Previous Symbol CUSIPN/A CIKN/A Webwww.bioasis.us Phone203-533-7082Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$460,000.00 Price / Sales36.32 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-24.62Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares67,860,000Market Cap$16.71 million Next Earnings Date7/24/2020 (Estimated) OptionableNot Optionable OTC:BIOAF Rates by TradingView Receive BIOAF News and Ratings via Email Sign-up to receive the latest news and ratings for BIOAF and its competitors with MarketBeat's FREE daily newsletter. biOasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions How has biOasis Technologies' stock been impacted by COVID-19 (Coronavirus)? biOasis Technologies' stock was trading at $0.1545 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIOAF shares have increased by 59.4% and is now trading at $0.2462. View which stocks have been most impacted by Coronavirus. When is biOasis Technologies' next earnings date? biOasis Technologies is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for biOasis Technologies. Has biOasis Technologies been receiving favorable news coverage? News stories about BIOAF stock have trended very negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. biOasis Technologies earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about biOasis Technologies. Who are some of biOasis Technologies' key competitors? Some companies that are related to biOasis Technologies include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), PetIQ (PETQ), Trxade Group (TRXD) and MultiCell Technologies (MEDS). View all competitors. Who are biOasis Technologies' key executives? biOasis Technologies' management team includes the following people: Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chair, CEO & Pres (Age 61)Ms. Christine Antalik, Chief Financial Officer (Age 48)Mr. Graeme Dick, Director of Investor RelationsMr. Kim Elton, Director of MarketingMr. Doug Williams MBA, Exec. VP & Chief Bus. Officer What is biOasis Technologies' stock symbol? biOasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF." How do I buy shares of biOasis Technologies? Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is biOasis Technologies' stock price today? One share of BIOAF stock can currently be purchased for approximately $0.25. How big of a company is biOasis Technologies? biOasis Technologies has a market capitalization of $16.71 million and generates $460,000.00 in revenue each year. What is biOasis Technologies' official website? The official website for biOasis Technologies is www.bioasis.us. How can I contact biOasis Technologies? biOasis Technologies' mailing address is 14 Water Street, Guilford CT, 6437. The company can be reached via phone at 203-533-7082 or via email at [email protected] This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
